| Target Professions: | MD, DO, Physician Associate/Assistant, Nurse Practitioner |
| Target Specialties: | Neurology |
| Credits Available: | 4.75 AMA PRA Category 1 Credit™/ MOC Points |
This interactive program equips neurology providers with practical strategies to improve care for patients with myasthenia gravis. Grounded in real-world clinical challenges, the content focuses on early identification of high-risk patients, individualized treatment planning, and effective integration of emerging therapies. Participants will gain insights that can be immediately applied to enhance outcomes across the spectrum of myasthenia gravis severity.
These questions are designed to help you reflect on key topics in MG diagnosis, available treatments, and ways to personalize care for your patients.
This module reviews the natural history, pathophysiology, and risk factors of MG. Learn how early recognition, antibody subtypes, and disease severity influence progression, treatment decisions, and long-term outcomes in patients with MG.
This module explores new and emerging therapies for MG, including monoclonal antibodies, complement inhibitors, and FcRn inhibitors. Learn how these therapies target the immune system to improve symptom management with a more favorable safety profile than traditional therapies.
This module explores how to individualize treatment for MG by evaluating response to standard therapies and identifying patients who may benefit from targeted therapeutic options. Learn how to tailor care based on antibody subtype, disease severity, and patient needs.
Reinforce your learning on myasthenia gravis—from identifying at-risk patients to personalizing treatment plans. This short activity helps solidify key takeaways to support your care decisions.
Explore early-stage gMG progression, diagnostic challenges, and the burden of delayed care through real-world patient experiences and clinician perspectives.
This activity features a 44-year-old woman with MG, whose symptoms worsen despite pyridostigmine, prednisone, and azathioprine. The patient case activity discusses strategies to manage refractory MG and when to consider alternative treatments.
This activity features a 62-year-old man with new-onset MuSK-positive MG who develops significant side effects from initial corticosteroid treatment.
Considering the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with myasthenia gravis (MG).
Discuss evolving treatment strategies for gMG, including the role of FcRn antagonists, patient perspectives on treatment decisions, the impact of disease burden on quality of life, and individualized treatment approaches with management of adverse events.
